Resveratrol supplement shows promise in improving quality of life in wet AMD

A new study suggests resveratrol oral supplementation can be an effective complementary treatment for patients suffering from wet age-related macular degeneration (AMD).

The research showed that patients who received resveratrol supplements demonstrated significant improvements in quality of life, specifically in areas related to anxiety, depression, and contrast sensitivity. While the number of required intravitreal injections remained consistent between the groups, the resveratrol supplement appeared to enhance the overall well-being of patients with wet AMD.

The study included 50 previously untreated patients with wet AMD, who were randomly divided into 2 groups. Both groups received 3 monthly intravitreal injections of 2.0 mg aflibercept (IAIs), followed by injections administered on an as-needed basis. One group also incorporated a daily regimen of 2 tablets of resveratrol oral supplement.

Over the course of 2 months, both groups received a comparable number of IAIs, with no significant variance noted (4.52±1.00 vs 4.28±0.90, P = 0.38).

However, patients who received resveratrol supplements demonstrated markedly improved scores in Hospital Anxiety and Depression Scale (HADS) Depression (11.88±2.51 vs 8.28±1.54, P < 0.001) and HADS Anxiety (11.92±2.52 vs 7.76±1.51, P<0.001) questionnaires. A statistically significant disparity was detected in the mean change from baseline values of contrast sensitivity (0.17±0.19 vs 0.35±0.24, P = 0.005), HADS Depression (0.08±1.38 vs -3.88±1.48, P < 0.001), and HADS Anxiety (0.36±1.98 vs -5.12±2.70, P < 0.001) scores, favoring patients treated with resveratrol supplements.

Reference
Datseris I, Bouratzis N, Kotronis C, et al. One-year outcomes of resveratrol supplement with aflibercept versus aflibercept monotherapy in wet age-related macular degeneration. Int J Ophthalmol. 2023;16(9):1496-1502. doi: 10.18240/ijo.2023.09.17. PMID: 37724273; PMCID: PMC10475632.